Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04679870 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral GB2064 in Participants With Myelofibrosis | PHASE2 | ACTIVE NOT_RECRUITING | 21 | — | — | Jun 9, 2021 | Jun 30, 2026 | Apr 3, 2024 | 11 | United States, Australia +2 |
Incidence and severity of adverse events as reported by investigators
| Arm | Type | Description |
|---|---|---|
| GB2064 | EXPERIMENTAL | GB2064 will be administered orally as 4 x 250 mg tablets twice a day. |
| Name | Type | Description |
|---|---|---|
| GB2064 | DRUG | GB2064 (formerly PAT-1251) is a high-affinity, selective, mechanism-based, small molecule inhibitor of LOXL2, administered twice a day |
Inclusion Criteria: Participants must satisfy all of the following criteria at the Screening visit: 1. Adult male or female participants ≥ 18 years of age at enrolment: 1. Female participants may be of non-childbearing potential defined as permanently sterile or postmenopausal, or female parti...